10.1089/ars.2013.5703 250 NeumannM.SampathuD
Acharya A, Vishwas S, Singh SK
While SLU-PP-332 shows promising results in oncology and neurodegenerative disorders, 5-amino-1mq has a more established track record in metabolic health and aging-related conditions
The choice of secretagogue shapes which of those variables stays quiet and in study designs where prolactin is part of the background biology, the compound selection has direct consequences for interpretation
Note that 9 mg and 12 mg are now the Phase-3-validated doses, while 1 mg, 4 mg, and 8 mg remain Phase 2 / research reference points
Harley Street Institute Train, read, and grow the practitioner's home for aesthetic medicine